The Authors Reply  by Shavit, Linda et al.
On the obituary for
George E. Schreiner
To the Editor: Drs Robert Rubin and Christopher Blagg have
brought to my attention an error in my obituary for George
E. Schreiner where I wrote ‘He is credited with demonstrating
a patient on dialysis to a Senate Select Subcommittee.’1
In fact, he opposed this move, which he considered reckless,
but was persuaded to supply a dialysis machine and the assis-
tance of one of his nephrology fellows. A full account of this
can be read in the chapter on ‘Origins of the Medicare Kidney
Disease Entitlement: The Social Security Amendments of
1972’ by Retting2 and Schreiner.3
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Aldosterone blockade: the heart
versus the kidney
To the Editor: We read with great interest the recent
comprehensive review from Shavit et al.1 on aldosterone
blockade. Their summary of the data on glomerular ﬁltration
rate from eight available studies (six randomized controlled
studies in a total of 326 patients given spironolactone, one
using eplerenone in 268 patients, and one retrospective study)
in patients with an estimated glomerular ﬁltration rate
(eGFR) of 430ml/min per 1.73m2 suggests no signiﬁcant
difference in eGFR with either spironolactone or eplerenone
in addition to angiotensin-converting enzyme inhibitor or
angiotensin receptor blockers, but a detriment in patients
with resistant hypertension of approximately 7.4ml/min per
1.73m2. The argument for this may perhaps relate to the
putative beneﬁcial effects of blockade of the signaling pathway
mediating insulin resistance, ﬁbrosis, and proteinuria,
independent of changes in blood pressure.
Interestingly, Rossignol et al.2 have recently analyzed the
data from the Eplerenone EPHESUS study. In a subset of
5792 patients, with mean age 64 years, baseline eGFR
70±21ml/min per 1.73m2 (33% o60ml/min per 1.73m2),
and mean blood pressure 119/72mmHg, they noted that in
patients with left ventricular systolic dysfunction with or at
high risk of heart failure in the post-infarction setting, there
was an early change in eGFR, and after 24 months follow-up
they noted a gradual deterioration in eGFR ranging from the
baseline value of 4.6±0.9ml/min for those on eplerenone
(Po0.0001) to 2.7±0.9ml/min for those in the placebo
group (P¼ 0.02), giving a mean difference of 1.4±0.3
ml/min (Po0.0001). The difference occurred early within the
ﬁrst month of treatment and persisted, and was independent
of blood pressure changes, but may relate to changes in
hemodynamics based on plasma volume changes, perhaps
similar to the ﬁndings of Pisoni et al.3 in patients with
resistant hypertension given aldosterone blockade.
Most importantly, the observed decline in eGFR was not
clinically detrimental over a 2-year period. Indeed, addition of
eplerenone to standard care improved the clinical outcomes
despite the slightly greater early reductions in eGFR, com-
pared with placebo.
We believe it is therefore important to highlight these
recent ﬁndings to the reader and add to this excellent review,
and to stress the importance of long-term data on clinical
cardiovascular outcomes in chronic kidney disease.
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The Authors Reply: We appreciate the positive interest of
Professor Bhandari1 in our recently published comprehensive
review on ‘Aldosterone blockade in the management of
patients with CKD’.2 The study of Rossignol et al.3 constitutes
a post hoc analysis of the EPHESUS study4 and evaluated
the effect of eplerenone on renal function and the inter-
action between changes in renal function, and subsequent
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cardiovascular outcomes, in patients with heart failure after an
acute myocardial infarction. Even though the average
estimated glomerular ﬁltration rate (eGFR) of these patients
was 70±21ml/min per 1.73m2, a large subset of these
patients had no established chronic kidney disease (CKD), and
data on proteinuria was not available. Only a third of the
studied patients had baseline eGFR less than 60ml/min per
1.73m2. Of interest, the subgroup of patients with eGFR
o60ml/min per 1.73m2 at baseline were not susceptible to
further renal functional deterioration. In addition, the effect of
eplerenone on renal function through different CKD stages
was not evaluated in this study. Only one patient with
worsening renal function was reported to manifest hyperka-
lemia (46mmol/l). Thus, although published after our review
was submitted, these newer results of Rossignol et al.3 are
consistent with and support the conclusions of our review.
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Urea handling in acute renal
failure
To the Editor: Bankir and Yang1 provided a very thought-
provoking account of renal physiology, linking structural and
functional details in a new and important way. Their
arguments in favor of active urea secretion in pars recta
of the proximal tubule seem particularly convincing. As
clinicians, we have been used to assessing the relative change
of concentrations of urea and creatinine to help in distingui-
shing pre-renal failure from acute tubular necrosis (ATN).
Bankir and Yang1 now state that in the case of ATN, blood
urea nitrogen (BUN) rises signiﬁcantly more than plasma
creatinine in comparison with pre-renal failure. This is not
the common interpretation. In a Nephrology Forum in the
Journal in 1998, RC Blantz discussed the pathophysiology of
pre-renal azotemia and wrote that pre-renal failure in
comparison with ATN was characterized by a high ratio of
BUN to serum creatinine.2 Dr Blantz analyzed the overall
situation in pre-renal failure as one in which glomerular
ﬁltration rate (GFR) and oxygen consumption in the
proximal tubule was reduced, citing the concept of Thurau
of ‘acute renal success’ in which the tubuloglomerular
feedback protected overworked oxygen-deprived tubules by
reducing GFR. Hence, it is entirely consistent with generalized
inhibition of active urea secretion as described in the paper by
Bankir and Yang. Also, as actual tubular necrosis is in fact a
rare ﬁnding in ‘acute tubular necrosis,’3 it is to be anticipated
that the active urea transport could be less inhibited in the
presence of ATN as compared with pre-renal failure. As
previously reported,4,5 this is in fact what has been observed: a
low fractional excretion of urea in pre-renal failure (o35%)
compared with ATN (440%).
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The Authors Reply: We are grateful to Ring1 for his
interesting comment about urea and creatinine handling in
acute renal failure. He presented more clearly than we did in
our paper,2 the description of the differences between pre-
renal failure and acute tubular necrosis (ATN). Actually, in the
normal kidney, the fractional excretion of urea (FEurea) depends
largely on a combination of inﬂuences exerted independently
on the proximal and the distal nephron. As already well known
since several decades, as shown in Figure 5 of our article,2 and
as re-emphasized by Carvounis et al.,3 a strong urea reab-
sorption occurs in the distal nephron at low urine ﬂow rates,
resulting in a dramatic fall in FEurea.
In pre-renal azotemia, FEurea may be strongly reduced
both by a decrease in proximal tubule function due to
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